Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT

• Published in: Endocrine oncology 2024-01, Vol.4 (1), p.e240001-8
• Main Authors: Nunez, Jose E, Ng, Sylvia, Chen, Hanbo, Singh, Simron, Hallet, Julie, Law, Calvin, Myrehaug, Sten
• Format: Article
• Language: English
• Subjects: neuroendocrine; peptide receptor radionuclide therapy; stereotactic body radiation therapy
• ISSN: 2634-4793; 2634-4793
• DOI: 10.1530/EO-24-0001

There is interest in optimizing peptide receptor radionuclide therapy (PRRT) for the management of metastatic neuroendocrine neoplasms (NEN). The addition of stereotactic body radiation therapy (SBRT) may provide synergistic benefits by targeting specific sites of disease that may represent areas of tumor heterogeneity. Little is known about the efficacy or potential toxicity of this approach; understanding the outcomes of patients treated with these two modalities in a sequential fashion will provide insights into the appropriateness of embarking on a combined therapy strategy. An institutional retrospective review of 21 patients with NEN treated with sequential PRRT and SBRT (64 targets) was performed. Median overall survival and progression-free survival were 19.6 months and 12.8 months, respectively. Median time to local recurrence at the SBRT site was not reached, with rates at 12 and 24 months of 1.8% and 5.9%, respectively. The toxicity profile remains favorable. Given the safety and efficacy of sequential SBRT and PRRT, further trials evaluating a concurrent treatment approach may be warranted.